FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2279707549> ?p ?o ?g. }

• W2279707549 endingPage "6617" @default.
• W2279707549 startingPage "6617" @default.
• W2279707549 abstract "6617 Objectives: Zoledronic acid (ZA) reduces the risk of skeletal-related events (SREs) in lung cancer patients with bone metastases and may improve survival among those patients with high levels of bone metabolism. This analysis assessed, from the UK National Health Service's perspective, the economic impact of ZA therapy in patients with bone metastases secondary to lung cancer. Methods: A literature-based decision analytic model was developed to compare the direct costs and quality adjusted life years (QALY) experienced by lung cancer patients with bone metastases receiving placebo or ZA. Survival, SRE incidence, and number of infusions administered were obtained from a randomized clinical trial comparing 4 mg ZA with placebo. Drug acquisition and administration costs and SRE costs were estimated using published sources and national fee schedules (i.e., NHS reference costs, British National Formulary, Personal Social Services Research Unit reference costs). The impact of SREs on quality of life was estimated using the literature. Consistent with previous economic analyses of bisphosphonates in cancers (e.g., Hillner et al, 2000), patients avoiding SREs were assumed to experience quality of life improvements for 1 month. Results: The average remaining life expectancy was conservatively assumed equal in both groups and was 8.50 months (median, 5.89 months). During those months, patients receiving placebo were projected to experience 2.07 SREs on average compared to 1.32 SREs among ZA patients. QALYs were estimated at 0.3523 per patient (pp) and 0.3350 pp in the ZA and placebo groups, respectively. ZA drug-related costs were estimated at £1,473 pp, based on 5.87 infusions pp and a cost of £251.01 per infusion. The use of ZA was associated with a reduction of £1,562 pp in SRE costs. Overall, ZA saved costs and increased QALYs compared to no therapy, by £89 pp and 0.0173 QALYs pp, respectively. In sensitivity analyses, ZA cost £25,000 or less per QALY under a wide range of assumptions. Conclusions: The use of ZA leads to fewer SREs, better estimated quality of life, and lower costs relative to placebo in UK lung cancer patients with bone metastases. The use of ZA in this population therefore appears highly cost effective. No significant financial relationships to disclose." @default.
• W2279707549 created "2016-06-24" @default.
• W2279707549 creator A5035664147 @default.
• W2279707549 creator A5049554190 @default.
• W2279707549 creator A5053493853 @default.
• W2279707549 creator A5087184017 @default.
• W2279707549 creator A5090256464 @default.
• W2279707549 date "2007-06-20" @default.
• W2279707549 modified "2023-10-16" @default.
• W2279707549 title "Economic value of zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer: The case of the United Kingdom (UK)" @default.
• W2279707549 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.6617" @default.
• W2279707549 hasPublicationYear "2007" @default.
• W2279707549 type Work @default.
• W2279707549 sameAs 2279707549 @default.
• W2279707549 citedByCount "9" @default.
• W2279707549 countsByYear W22797075492013 @default.
• W2279707549 countsByYear W22797075492014 @default.
• W2279707549 countsByYear W22797075492017 @default.
• W2279707549 countsByYear W22797075492018 @default.
• W2279707549 crossrefType "journal-article" @default.
• W2279707549 hasAuthorship W2279707549A5035664147 @default.
• W2279707549 hasAuthorship W2279707549A5049554190 @default.
• W2279707549 hasAuthorship W2279707549A5053493853 @default.
• W2279707549 hasAuthorship W2279707549A5087184017 @default.
• W2279707549 hasAuthorship W2279707549A5090256464 @default.
• W2279707549 hasConcept C100406419 @default.
• W2279707549 hasConcept C121608353 @default.
• W2279707549 hasConcept C126322002 @default.
• W2279707549 hasConcept C133925201 @default.
• W2279707549 hasConcept C141071460 @default.
• W2279707549 hasConcept C142724271 @default.
• W2279707549 hasConcept C159110408 @default.
• W2279707549 hasConcept C204787440 @default.
• W2279707549 hasConcept C27081682 @default.
• W2279707549 hasConcept C2776125615 @default.
• W2279707549 hasConcept C2776256026 @default.
• W2279707549 hasConcept C2776326535 @default.
• W2279707549 hasConcept C2779951463 @default.
• W2279707549 hasConcept C2908647359 @default.
• W2279707549 hasConcept C512399662 @default.
• W2279707549 hasConcept C71924100 @default.
• W2279707549 hasConcept C99454951 @default.
• W2279707549 hasConceptScore W2279707549C100406419 @default.
• W2279707549 hasConceptScore W2279707549C121608353 @default.
• W2279707549 hasConceptScore W2279707549C126322002 @default.
• W2279707549 hasConceptScore W2279707549C133925201 @default.
• W2279707549 hasConceptScore W2279707549C141071460 @default.
• W2279707549 hasConceptScore W2279707549C142724271 @default.
• W2279707549 hasConceptScore W2279707549C159110408 @default.
• W2279707549 hasConceptScore W2279707549C204787440 @default.
• W2279707549 hasConceptScore W2279707549C27081682 @default.
• W2279707549 hasConceptScore W2279707549C2776125615 @default.
• W2279707549 hasConceptScore W2279707549C2776256026 @default.
• W2279707549 hasConceptScore W2279707549C2776326535 @default.
• W2279707549 hasConceptScore W2279707549C2779951463 @default.
• W2279707549 hasConceptScore W2279707549C2908647359 @default.
• W2279707549 hasConceptScore W2279707549C512399662 @default.
• W2279707549 hasConceptScore W2279707549C71924100 @default.
• W2279707549 hasConceptScore W2279707549C99454951 @default.
• W2279707549 hasIssue "18_suppl" @default.
• W2279707549 hasLocation W22797075491 @default.
• W2279707549 hasOpenAccess W2279707549 @default.
• W2279707549 hasPrimaryLocation W22797075491 @default.
• W2279707549 hasRelatedWork W1993489427 @default.
• W2279707549 hasRelatedWork W2002120878 @default.
• W2279707549 hasRelatedWork W2003938723 @default.
• W2279707549 hasRelatedWork W2047967234 @default.
• W2279707549 hasRelatedWork W2101347557 @default.
• W2279707549 hasRelatedWork W2118496982 @default.
• W2279707549 hasRelatedWork W2294199562 @default.
• W2279707549 hasRelatedWork W2439875401 @default.
• W2279707549 hasRelatedWork W4238867864 @default.
• W2279707549 hasRelatedWork W2525756941 @default.
• W2279707549 hasVolume "25" @default.
• W2279707549 isParatext "false" @default.
• W2279707549 isRetracted "false" @default.
• W2279707549 magId "2279707549" @default.
• W2279707549 workType "article" @default.